Literature DB >> 7142703

Chemotactic factors trigger their own oxidative inactivation by human neutrophils.

R A Clark.   

Abstract

Human neutrophils exposed to phagocytosable particles or soluble activating agents are able to inactivate chemotactic factors. The present experiments demonstrate that the peptide chemoattractant, f-met-leu-phe, serves as a sufficient secretory stimulus to trigger its own functional inactivation by neutrophils. This phenomenon is dependent on the concentration of the chemoattractant and the duration of its exposure to neutrophils. It requires low numbers of viable neutrophils and physiologic concentrations of chloride and is blocked by addition of azide, cyanide, catalase, or methionine, but not methionine sulfoxide, superoxide dismutase, or heated catalase. Neutrophils from patients with myeloperoxidase deficiency of chronic granulomatous disease are not able to inactivate the chemotactic factor unless purified myeloperoxidase or hydrogen peroxide, respectively, is added. Thus, chemotactic peptides can trigger neutrophils to secrete myeloperoxidase and hydrogen peroxide, which together with a halide destroy the biologic activity of the peptide, probably by oxidizing a methionine residue. These observations support the pathophysiologic significance of oxidative inactivation of humoral mediators as a negative feedback inflammatory control mechanism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7142703

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Stimulation of neutrophil elastase and myeloperoxidase release by IgG fragments.

Authors:  I Eckle; G Kolb; C Heiser; K Havemann
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

2.  Receptor-dependent and -independent immunomodulatory effects of phenol-soluble modulin peptides from Staphylococcus aureus on human neutrophils are abrogated through peptide inactivation by reactive oxygen species.

Authors:  Huamei Forsman; Karin Christenson; Johan Bylund; Claes Dahlgren
Journal:  Infect Immun       Date:  2012-03-19       Impact factor: 3.441

Review 3.  Role of superoxide dismutase in modification of radiation injury.

Authors:  A Petkau
Journal:  Br J Cancer Suppl       Date:  1987-06

4.  Oxidation of methionine residues in proteins of activated human neutrophils.

Authors:  H Fliss; H Weissbach; N Brot
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

5.  Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver.

Authors:  K E Brown; E M Brunt; J W Heinecke
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

6.  Ascorbate and cysteine-mediated selective neutralisation of extracellular oxidants during N-formyl peptide activation of human phagocytes.

Authors:  R Anderson; P T Lukey; A J Theron; U Dippenaar
Journal:  Agents Actions       Date:  1987-02

7.  Neutrophils may directly synthesize both H2O2 and O2- since surface stimuli induce their release in stimulus-specific ratios.

Authors:  S T Hoffstein; D E Gennaro; R M Manzi
Journal:  Inflammation       Date:  1985-12       Impact factor: 4.092

8.  Response of neutrophils to stimulus infusion: differential sensitivity of cytoskeletal activation and oxidant production.

Authors:  G M Omann; L A Sklar
Journal:  J Cell Biol       Date:  1988-09       Impact factor: 10.539

9.  Benoxaprofen activates membrane-associated oxidative metabolism in human polymorphonuclear leucocytes by apparent modulation of protein kinase C.

Authors:  P T Lukey; R Anderson; U H Dippenaar
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

10.  Activation of the respiratory burst enzyme in human polymorphonuclear leukocytes by chemoattractants and other soluble stimuli. Evidence that the same oxidase is activated by different transductional mechanisms.

Authors:  L C McPhail; R Snyderman
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.